Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 669 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Resource Round-Up: 2Unstoppable May 16, 2023 New Research in Treating Non-Small Cell Lung Cancer: 2022 North America... December 1, 2022 Time to get stratified January 10, 2023 Health inequalities: breaking down barriers to cancer screening September 23, 2022 Load more HOT NEWS Why Cancer Survivors Should Have a Written Survivorship Care Plan The Pesticide Chemical Responsible For Mass Bee Die-Offs Is Killing Birds... NEOSTAR Results Indicate that Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses... EMA Recommends Granting a Marketing Authorisation for Tisotumab Vedotin
